Recent concepts in non-alcoholic fatty liver disease

Diabetic Medicine

Volumn 22, Issue 9, 2005, Pages 1129-1133

  Adams, L A ^a   Angulo, Paul ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MAYO CLINIC   (United States)

Author keywords

Cirrhosis; Diabetes; Non alcoholic fatty liver disease; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; BETAINE; INSULIN SENSITIZING AGENT; LIPOPOLYSACCHARIDE; LIVER PROTECTIVE AGENT; LOSARTAN; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; ROSIGLITAZONE;

CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXERCISE; GLUCOSE INTOLERANCE; HEPATITIS; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; VASCULAR DISEASE; WEIGHT REDUCTION;

FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER; METABOLIC SYNDROME X; OXIDATIVE STRESS; RISK FACTORS;

EID: 24044536090     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01748.x     Document Type: Review

References (52)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
2. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005; 22: 1141-1145.
3. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1428-1432.
4. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40: 2002-2009.
5. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
6. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
7. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127: S97-103.
8. Azzout-Marniche D, Becard D, Guichard C, Foretz M, Ferre P, Foufelle F. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J 2000; 350: 389-393.
9. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152.
10. Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003; 38: 133-140.
11. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in non-alcoholic steatohepatitis. Hepatology 2002; 35: 898-904.
12. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353.
13. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005; 280: 9887-9894.
14. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N et al. Non-alcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-372.
15. Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T et al. Chronological development of elevated aminotransferases in a non-alcoholic population. Hepatology 2005; 41: 64-71.
16. Targher G, Bertolini E, Zoppini G, Zenari L, Falezza G. Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients. Diabet Med 2005; 22: 1146-1150.
17. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 1997; 349: 1210-1213.
18. Adams EA, Feldstein A, Eindor KD, Angulo P. Non-alcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004; 39: 909-914.
19. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998; 114: 842-825.
20. Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2002; 16: 709-731.
21. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD et al. Hepatocyte apoptosis and fas expression are prominent features of human non-alcoholic steatohepatitis. Gastroenterology 2003; 125: 437-443.
22. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway. Hepatology 2004; 40: 185-194.
23. Valenti E, Fracanzani AE, Dongiovanni P, Santorelli G, Branchi A, Taioli E et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in non-alcoholic fatty liver disease. Gastroenterology 2002; 122: 274-280.
24. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211.
25. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 2004; 40: 46-54.
26. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004; 40: 386-393.
27. Neuschwander-Tetri BA, Caldwell SH. Non-alcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
28. Jepsen P, Vilstrup H, Mellemkjaer E, Thulstrup AM, Olsen JH, Baron JA et al. Prognosis of patients with a diagnosis of fatty liver - a registry-based cohort study. Hepatogastroenterology 2003; 50: 2101-2104.
29. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755.
30. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719.
31. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
32. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Non-alcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2: 262-265.
33. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
34. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of non-alcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-138.
35. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354.
36. Ioannou G, Weiss N, Boyko E, Kahn S, Lee S. Contribution of metabolic factors to alanine aminotransaminase activity in persons with other causes of liver disease. Gastroenterology 2005; 128: 627-635.
37. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA et al. Clinical and histologic spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
38. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
39. Kim D-J, Noh J-H, Cho N-H, Lee B-W, Choi Y-H, Jung J-H et al. Serum γ-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Diabet Med 2005; 22: 1134-1140.
40. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539-543.
41. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-468.
42. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
43. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111: 473-478.
44. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol 2004; 99: 1316-1320.
45. Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother 2003; 4: 611-623.
46. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Non-alcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-1654.
47. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-1090.
48. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003; 38: 1008-1017.
49. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. Hepatology 2004; 39: 188-196.
50. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-1115.
51. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490.
52. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with non-alcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225.